TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31375459

Group type: EXPERIMENTAL
Intervention: Cryolipolysis (one session at -10°C for 50 minutes)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 29073323

Group type: EXPERIMENTAL
Intervention: Spot (Nac‐)5‐ASA urinalysis by HPLC
Number of subjects: 29
Study: 26614120

Group type: EXPERIMENTAL
Intervention: Acute one-legged exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin stimulation after acute exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 weeks of one-legged exercise training
Number of subjects: 0
Study: 23772874

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe) administered to patients with severe liver cirrhosis (CP C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe) administered to patients with moderate liver cirrhosis (CP B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (patients without liver disease)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of Child-Pugh and MELD scores with unbound midazolam clearance
Number of subjects: 30
Study: 21883386

Group type: EXPERIMENTAL
Intervention: Domperidone 10mg, four doses daily, at 4h intervals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200mg 12‐hourly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Domperidone and ketoconazole together
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21189775

Group type: EXPERIMENTAL
Intervention: Schwarz appliance treatment (expanded group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (non-expanded)
Number of subjects: 28
Study: 18672634

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard whipple operation (SW)
Number of subjects: 27
Study: 15983525

Group type: EXPERIMENTAL
Intervention: Walnut-specific (modified low fat including 30 g walnuts/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Modified low-fat (total diet advice using exchange lists to differentiate PUFA-rich foods)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-fat (general advice)
Number of subjects: 55
Study: 12463724

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of almotriptan (3 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of almotriptan (6 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral administration of almotriptan (25 mg)
Number of subjects: 18
Study: 11783210

Group type: EXPERIMENTAL
Intervention: Gubiyin (GBY)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indomethacin (control)
Number of subjects: 70
Study: 7540696

Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/kg body weight per day)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg body weight per day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 121
Study: 1835930

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, three times a day for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 726859

Group type: EXPERIMENTAL
Intervention: Barbiturates (pentobarbital premedication and thiopental induction)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (halothane and nitrous oxide only)
Number of subjects: 28
Study: 30674486

Group type: EXPERIMENTAL
Intervention: Community randomised trial intervention to improve school hearing screening and referral process, details on dosage and duration not specified.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Qualitative and mixed methods components including focus groups and community events.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stakeholder interviews with parents, children, teachers, school administrators, and community health aides.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Concluding focus groups with policymakers, healthcare administrators, and community leaders.
Number of subjects: 15
Study: 27988806

Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride (strong centrally acting anticholinergic)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide (moderate centrally acting anticholinergic)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (anticholinergic devoid of central properties)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26181658

Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 23497838

Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study: 21530875

Group type: EXPERIMENTAL
Intervention: European Bermuda grass extract
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: European cat extract
Number of subjects: 6

Group type: COMPARATOR
Intervention: US FDA reference extract
Number of subjects: 6
Study: 18533155

Group type: EXPERIMENTAL
Intervention: Educational toolbox intervention
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reference organization (no toolbox)
Number of subjects: 2
Study: 17243195

Group type: EXPERIMENTAL
Intervention: OD1 (20 mg once daily with a 1-step up-titration)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: OD3 (20 mg once daily with a 3-step up-titration)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: BID3 (10 mg twice daily with a 3-step up-titration)
Number of subjects: 78
Study: 15071282

Group type: EXPERIMENTAL
Intervention: Virosome-adjuvanted influenza vaccine
Number of subjects: 453

Group type: COMPARATOR
Intervention: Split influenza vaccine
Number of subjects: 453
Study: 11679510

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 800

Group type: COMPARATOR
Intervention: Clinical touch method
Number of subjects: 800
Study: 9629991

Group type: EXPERIMENTAL
Intervention: Ranid (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zantac (300 mg)
Number of subjects: 24
Study: 8159781

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml in 100 ml physiological saline i.v. once a day from Monday to Friday for four weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (130 ml physiological saline)
Number of subjects: 120
Study: 3124685

Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 31
Study: 31435732

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyeloplasty (LP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Robotic-assisted laparoscopic pyeloplasty (RALP)
Number of subjects: 53
Study: 29399852

Group type: EXPERIMENTAL
Intervention: Task analysis‐based training (small-group session and e-learning)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual educational approach (Control)
Number of subjects: 124
Study: 28932907

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous Training (CT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 26577969

Group type: EXPERIMENTAL
Intervention: Camel milk therapy for 2 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22993051

Group type: EXPERIMENTAL
Intervention: Yogic breathing exercise (YBG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Video control (VCG)
Number of subjects: 96
Study: 21575465

Group type: EXPERIMENTAL
Intervention: Nedaplatin plus 5‐fluorouracil (NF group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cisplatin plus 5‐fluorouracil (PF group)
Number of subjects: 100
Study: 18457800

Group type: EXPERIMENTAL
Intervention: Staff willingness to facilitate research
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Facility characteristics
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Function measures (Late Life FDI scale, timed-up-and-go, FICSIT balance scale, Elderly Mobility Scale)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Quality of Life measures (EuroQol quality of life scale, Life Satisfaction Index)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Falls assessment (audit of the medical record)
Number of subjects: 682
Study: 17031505

Group type: EXPERIMENTAL
Intervention: Microalbuminuric group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoalbuminuric group
Number of subjects: 40
Study: 14979753

Group type: EXPERIMENTAL
Intervention: Intervening treatment with varying number of memory retrievals
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intervening treatment with time allowed for memory retrievals
Number of subjects: 7
Study: 11681505

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycin-C (0.4 mg/ml for 2.5 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trabeculectomy alone (Control)
Number of subjects: 22
Study: 9444745

Group type: EXPERIMENTAL
Intervention: Oral fluconazole (100 mg followed by 50 mg/day for 14 days) with catheter replacement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Catheter replacement alone
Number of subjects: 30
Study: 7625301

Group type: EXPERIMENTAL
Intervention: clemastine (2mg orally)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: mepyramine (2 micrograms intradermally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 2893930

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 0
Study: 30616613

Group type: EXPERIMENTAL
Intervention: Daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 40
Study: 25760154

Group type: EXPERIMENTAL
Intervention: Cooled group (7 subjects) immersed forearms in cold water (10±1°C) for 20 min after exercises
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncooled group (7 subjects)
Number of subjects: 14
Study: 24284309

Group type: EXPERIMENTAL
Intervention: HI-SPI (SPI > 50)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LO-SPI (SPI < 50)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both HI-SPI and LO-SPI
Number of subjects: 42
Study: 22763424

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 810
Study: 19568715

Group type: EXPERIMENTAL
Intervention: TXYF granule, one package twice a day for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Miyarisan, two tablets three times a day for 4 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TXYF granule
Number of subjects: 120
Study: 17703830

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 210
Study: 16167226

Group type: EXPERIMENTAL
Intervention: Upper abdomen median incision
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined left thoracotomy and abdomen incision
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined viscera excision
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Radical resection
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis involving abdominal cavity
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis involving thoracic cavity
Number of subjects: 63
Study: 12399622

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (PGI(2))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 9697724

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9) gel applied daily for 2 weeks
Number of subjects: 0
Study: 11271222

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 545

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: FK 506 and CBIR
Number of subjects: 545
Study: 3176107

Group type: EXPERIMENTAL
Intervention: Standard one‐compartmental model calculations after a single dose of theophylline syrup (mean dose 413 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low theophylline dosage regimen (twice daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medium theophylline dosage regimen (twice daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High theophylline dosage regimen (twice daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bayesian analysis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Drug nomogram
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (2‐month duration)
Number of subjects: 33
Study: 31158271

Group type: EXPERIMENTAL
Intervention: Ustekinumab (q12w)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Ustekinumab (q8w)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall)
Number of subjects: 567
Study: 29986347

Group type: EXPERIMENTAL
Intervention: Telephone-based psychological counselling service
Number of subjects: 0
Study: 28299001

Group type: EXPERIMENTAL
Intervention: Loteprednol 0.5%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 62
Study: 25733274

Group type: EXPERIMENTAL
Intervention: Finasteride (3 years treatment)
Number of subjects: 670
Study: 23742033

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 Gy x 5) followed by full-dose chemotherapy (capecitabine and oxaliplatin) in 6 cycles before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard arm: chemoradiation (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) preoperatively, followed by selective postoperative adjuvant chemotherapy (optional)
Number of subjects: 0
Study: 21967987

Group type: EXPERIMENTAL
Intervention: Dopamine D(2/3) receptor agonist (pramipexole, 0.5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dopamine D(2/3) receptor antagonist (amisulpride, 400 mg)
Number of subjects: 18
Study: 18430206

Group type: COMPARATOR
Intervention: Not applicable (no intervention was tested)
Number of subjects: 636
Study: 16390899

Group type: EXPERIMENTAL
Intervention: Quality improvement program (medication)
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Quality improvement program (therapy)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Quality improvement program (medication/therapy)
Number of subjects: 1356
Study: 14657758

Group type: EXPERIMENTAL
Intervention: NVP given OW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: NVP given TW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: NVP given OD (2 mg/kg from birth to 14 days, upward arrow to 4 mg/kg from 15 days to 24 weeks)
Number of subjects: 75
Study: 10992173

Group type: EXPERIMENTAL
Intervention: 2 mg 17beta‐estradiol + 25 microg gestodene (group 2/25s)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol + 50 microg gestodene (group 2/50s)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 25 microg gestodene (group 1/25s)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 25 mg gestodene (group 1/25c)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 9238726

Group type: EXPERIMENTAL
Intervention: Physiotherapy three times a week for 5 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study: 1361068

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms twice daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 350
Study: 6365965

Group type: EXPERIMENTAL
Intervention: Lysis-centrifugation system processed within 9 hours
Number of subjects: 5125

Group type: COMPARATOR
Intervention: Lysis-centrifugation system processed after 9 hours
Number of subjects: 5125
Study: 30355209

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 27990506

Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular Platform (RP) group
Number of subjects: 18
Study: 24356749

Group type: EXPERIMENTAL
Intervention: Glibenclamide treatment for 48 weeks
Number of subjects: 747
Study: 22104012

Group type: EXPERIMENTAL
Intervention: Medication plus Deep Brain Stimulation (ODT + DBS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Optimal Drug Therapy (ODT)
Number of subjects: 30
Study: 20339970

Group type: EXPERIMENTAL
Intervention: Nesiritide (loading dose 0.5 microg/kg, maintenance dose 0.0075 microg/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nesiritide and Nitroprusside
Number of subjects: 60
Study: 18303248

Group type: EXPERIMENTAL
Intervention: Carotid and transcranial color-coded duplex ultrasonography (CDUS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 19
Study: 15820796

Group type: EXPERIMENTAL
Intervention: Midluteally started triptorelin administration continued until the first day of hMG treatment (group S)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Midluteally started triptorelin administration continued up to and including the fourth day of hMG treatment (group M)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Midluteally started triptorelin administration continued until the day of hCG injection (group L)
Number of subjects: 178
Study: 14530749

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (isonitrogenous mixture)
Number of subjects: 45
Study: 10737371

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 0
Study: 9275353

Group type: EXPERIMENTAL
Intervention: Breathing exercise (Group I)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 324
Study: 1320740

Group type: EXPERIMENTAL
Intervention: Formalin-inactivated hepatitis A vaccine
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1037
Study: 6365465

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Flupredniden acetate
Number of subjects: 55
Study: 30825966

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 22
Study: 30290717

Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (MSCs) from healthy donors, 90 million cells infused intravenously during high and very high activity disease flare-ups, followed by 9 months of follow-up.
Number of subjects: 3
Study: 27593185

Group type: EXPERIMENTAL
Intervention: IDEAL-CPMG
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dixon
Number of subjects: 33
Study: 24224997

Group type: EXPERIMENTAL
Intervention: TARGIT (targeted intraoperative radiotherapy)
Number of subjects: 3451

Group type: COMPARATOR
Intervention: EBRT (whole-breast external beam radiotherapy)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: TARGIT (prepathology)
Number of subjects: 3451

Group type: COMPARATOR
Intervention: EBRT (control for prepathology)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: TARGIT (postpathology)
Number of subjects: 3451

Group type: COMPARATOR
Intervention: EBRT (control for postpathology)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 3451

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 3451
Study: 22738023

Group type: EXPERIMENTAL
Intervention: Gum chewing preoperatively and in the direct postoperative phase
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20333892

Group type: EXPERIMENTAL
Intervention: Encoding strategy task with remote eye-tracking device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flanker task measuring resistance to interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task measuring inhibition of attention to task-irrelevant stimuli (distractibility)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic aspects of attentional control
Number of subjects: 0
Study: 17393526

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups combined (IFN-gamma 1b and placebo)
Number of subjects: 245
Study: 15871638

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (0.25 g twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: HAART alone (control)
Number of subjects: 17
Study: 11953727

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (I‐NO) at doses of 5, 20, and 80 ppm
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: COMPARATOR
Intervention: Both I‐NO and placebo
Number of subjects: 155
Study: 11153578

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8819276

Group type: EXPERIMENTAL
Intervention: T tube drainage during bile duct reconstruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: No T tube drainage during bile duct reconstruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 1433876

Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms.kg‐1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 32